Skip to main content
Top
Published in: Diabetology & Metabolic Syndrome 1/2014

Open Access 01-12-2014 | Research

The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c

Authors: Feng Xu, Li-hua Zhao, Jian-bin Su, Tong Chen, Xue-qin Wang, Jin-feng Chen, Gang Wu, Yan Jin, Xiao-hua Wang

Published in: Diabetology & Metabolic Syndrome | Issue 1/2014

Login to get access

Abstract

Background

Diabetic peripheral neuropathy (DPN) is one of the most common microvascular complications of diabetes. Glycemic variability could be an independent risk factor for diabetes complications in addition to average glucose. Type 2 diabetes with well-controlled glycosylated hemoglobin A1c (HbA1c) may have different terms of glycemic variability and vascular complication consequences. The aim of the study is to investigate the relationship between glycemic variability and DPN in type 2 diabetes with well-controlled HbA1c (HbA1c < 7.0%).

Methods

45 type 2 diabetes with well-controlled HbA1c(HbA1c < 7.0%) and with DPN (DM/DPN group) were recruited in the study, and 45 type 2 diabetes with well-controlled HbA1c and without DPN (DM/–DPN group) were set as controls. The two groups were also matched for age and diabetic duration. Blood pressure, body mass index(BMI), insulin sensitivity index (Matsuda index, ISI), total cholesterol (TC), triglyceride (TG), high density lipoprotein cholesterol (HDLC), and low density lipoprotein cholesterol (LDLC) were tested in the two groups. And all patients were monitored using the continuous glucose monitoring (CGM) system for consecutive 72 hours. The multiple parameters of glycemic variability included the standard deviation of blood glucose (SDBG), mean of daily differences (MODD) and mean amplitude of glycemic excursions (MAGE).

Results

The DM/DPN group had a greater SDBG, MODD and MAGE, when compared to the DM/–DPN group (p < 0.05). BMI, TC, and LDLC of DM/DPN group were lower than those of DM/–DPN group (p < 0.05). The patients with hypoglycemia were comparable between the two groups (p > 0.05). Univariate analysis showed DPN was closely associated with BMI (OR 0.82, CI 0.72–0.94, p = 0.005), TC (OR 0.63, CI 0.42–0.93, p = 0.02), LDLC (OR 0.4, CI 0.20–0.80, p = 0.009), SDBG (OR 2.95, CI 1.55–5.61, p = 0.001), MODD (OR 4.38, CI 1.48–12.93, p = 0.008), MAGE (OR 2.18, CI 1.47–3.24, p < 0.001). Multivariate logistic regression analysis showed that MAGE (OR 2.05, CI 1.36–3.09, p = 0.001) and BMI (OR 0.85, CI 0.73–0.99, p = 0.033) were significantly correlating with DPN. Glycemic variability, evaluated by MAGE, was the most significantly independent risk factor for DPN.

Conclusions

There was a close relationship between glycemic variability evaluated by MAGE and DPN in type 2 diabetes with well-controlled HbA1c.
Literature
1.
go back to reference Carrington AL, Shaw JE, Van Schie CH, Abbott CA, Vileikyte L, Boulton AJ: Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period?. Diabetes Care. 2002, 25: 2010-2015. 10.2337/diacare.25.11.2010.CrossRefPubMed Carrington AL, Shaw JE, Van Schie CH, Abbott CA, Vileikyte L, Boulton AJ: Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period?. Diabetes Care. 2002, 25: 2010-2015. 10.2337/diacare.25.11.2010.CrossRefPubMed
2.
go back to reference Boulton AJ, Malik RA, Arezzo JC, Sosenko JM: Diabetic somatic neuropathies. Diabetes Care. 2004, 27: 1458-1486. 10.2337/diacare.27.6.1458.CrossRefPubMed Boulton AJ, Malik RA, Arezzo JC, Sosenko JM: Diabetic somatic neuropathies. Diabetes Care. 2004, 27: 1458-1486. 10.2337/diacare.27.6.1458.CrossRefPubMed
3.
go back to reference Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D, American Diabetes Association: Diabetic neuropathies: a statement by the american diabetes association. Diabetes Care. 2005, 28: 956-962. 10.2337/diacare.28.4.956.CrossRefPubMed Boulton AJ, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegler D, American Diabetes Association: Diabetic neuropathies: a statement by the american diabetes association. Diabetes Care. 2005, 28: 956-962. 10.2337/diacare.28.4.956.CrossRefPubMed
4.
go back to reference Tesfaye S, Vileikyte L, Rayman G, Sindrup S, Perkins B, Baconja M, Vinik A, Boulton A, on behalf of the Toronto Expert Panel on Diabetic Neuropathy: Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011, 27: 629-638. 10.1002/dmrr.1225.CrossRefPubMed Tesfaye S, Vileikyte L, Rayman G, Sindrup S, Perkins B, Baconja M, Vinik A, Boulton A, on behalf of the Toronto Expert Panel on Diabetic Neuropathy: Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011, 27: 629-638. 10.1002/dmrr.1225.CrossRefPubMed
5.
go back to reference Candrilli SD, Davis KL, Kan HJ, Lucero MA, Rousculp MD: Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complicat. 2007, 21: 306-314. 10.1016/j.jdiacomp.2006.08.002.CrossRefPubMed Candrilli SD, Davis KL, Kan HJ, Lucero MA, Rousculp MD: Prevalence and the associated burden of illness of symptoms of diabetic peripheral neuropathy and diabetic retinopathy. J Diabetes Complicat. 2007, 21: 306-314. 10.1016/j.jdiacomp.2006.08.002.CrossRefPubMed
6.
go back to reference Wang DD, Bakhotmah BA, Hu FB, Alzahrani HA: Prevalence and correlates of diabetic peripheral neuropathy in a saudi arabic population: a cross-sectional study. PLoS One. 2014, 9: e106935-10.1371/journal.pone.0106935.PubMedCentralCrossRefPubMed Wang DD, Bakhotmah BA, Hu FB, Alzahrani HA: Prevalence and correlates of diabetic peripheral neuropathy in a saudi arabic population: a cross-sectional study. PLoS One. 2014, 9: e106935-10.1371/journal.pone.0106935.PubMedCentralCrossRefPubMed
7.
go back to reference Won JC, Kwon HS, Kim CH, Lee JH, Park TS, Ko KS, Cha BY: Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with Type 2 diabetes in Korea. Diabet Med. 2012, 29: e290-e296. 10.1111/j.1464-5491.2012.03697.x.CrossRefPubMed Won JC, Kwon HS, Kim CH, Lee JH, Park TS, Ko KS, Cha BY: Prevalence and clinical characteristics of diabetic peripheral neuropathy in hospital patients with Type 2 diabetes in Korea. Diabet Med. 2012, 29: e290-e296. 10.1111/j.1464-5491.2012.03697.x.CrossRefPubMed
8.
go back to reference Monnier L, Colette C, Owens DR: Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. Diabetes Metab Res Rev. 2009, 25: 393-402. 10.1002/dmrr.962.CrossRefPubMed Monnier L, Colette C, Owens DR: Integrating glycaemic variability in the glycaemic disorders of type 2 diabetes: a move towards a unified glucose tetrad concept. Diabetes Metab Res Rev. 2009, 25: 393-402. 10.1002/dmrr.962.CrossRefPubMed
9.
go back to reference Brownlee M, Hirsch IB: Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA. 2006, 295: 1707-1708. 10.1001/jama.295.14.1707.CrossRefPubMed Brownlee M, Hirsch IB: Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA. 2006, 295: 1707-1708. 10.1001/jama.295.14.1707.CrossRefPubMed
10.
go back to reference Nalysnyk L, Hernandez-Medina M, Krishnarajah G: Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010, 12: 288-298. 10.1111/j.1463-1326.2009.01160.x.CrossRefPubMed Nalysnyk L, Hernandez-Medina M, Krishnarajah G: Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010, 12: 288-298. 10.1111/j.1463-1326.2009.01160.x.CrossRefPubMed
12.
go back to reference Klonoff DC, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, Wolpert H, Endocrine Society: Continuous glucose monitoring: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011, 96: 2968-2979. 10.1210/jc.2010-2756.CrossRefPubMed Klonoff DC, Buckingham B, Christiansen JS, Montori VM, Tamborlane WV, Vigersky RA, Wolpert H, Endocrine Society: Continuous glucose monitoring: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011, 96: 2968-2979. 10.1210/jc.2010-2756.CrossRefPubMed
13.
go back to reference Mauras N, Fox L, Englert K, Beck RW: Continuous glucose monitoring in type 1 diabetes. Endocrine. 2013, 43: 41-50. 10.1007/s12020-012-9765-1.CrossRefPubMed Mauras N, Fox L, Englert K, Beck RW: Continuous glucose monitoring in type 1 diabetes. Endocrine. 2013, 43: 41-50. 10.1007/s12020-012-9765-1.CrossRefPubMed
14.
15.
go back to reference Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P, Toronto Diabetic Neuropathy Expert Group: Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010, 33: 2285-2293. 10.2337/dc10-1303.PubMedCentralCrossRefPubMed Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempler P, Lauria G, Malik RA, Spallone V, Vinik A, Bernardi L, Valensi P, Toronto Diabetic Neuropathy Expert Group: Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010, 33: 2285-2293. 10.2337/dc10-1303.PubMedCentralCrossRefPubMed
16.
go back to reference Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR: Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther. 2011, 13: 921-928. 10.1089/dia.2010.0247.PubMedCentralCrossRefPubMed Hill NR, Oliver NS, Choudhary P, Levy JC, Hindmarsh P, Matthews DR: Normal reference range for mean tissue glucose and glycemic variability derived from continuous glucose monitoring for subjects without diabetes in different ethnic groups. Diabetes Technol Ther. 2011, 13: 921-928. 10.1089/dia.2010.0247.PubMedCentralCrossRefPubMed
17.
go back to reference Zhou J, Jia W, Bao Y, Ma X, Lu W, Li H, Hu C, Xiang K: Glycemic variability and its responses to intensive insulin treatment in newly diagnosed type 2 diabetes. Med Sci Monit. 2008, 14: CR552-CR558.PubMed Zhou J, Jia W, Bao Y, Ma X, Lu W, Li H, Hu C, Xiang K: Glycemic variability and its responses to intensive insulin treatment in newly diagnosed type 2 diabetes. Med Sci Monit. 2008, 14: CR552-CR558.PubMed
18.
go back to reference Zhou J, Li H, Ran X, Yang W, Li Q, Peng Y, Li Y, Gao X, Luan X, Wang W, Jia W: Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring. Med Sci Monit. 2011, 17: CR9-CR13.PubMedCentralPubMed Zhou J, Li H, Ran X, Yang W, Li Q, Peng Y, Li Y, Gao X, Luan X, Wang W, Jia W: Establishment of normal reference ranges for glycemic variability in Chinese subjects using continuous glucose monitoring. Med Sci Monit. 2011, 17: CR9-CR13.PubMedCentralPubMed
19.
go back to reference Monnier L, Mas E, Ginet C, Michel F, Villo LN, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006, 295: 1681-1687. 10.1001/jama.295.14.1681.CrossRefPubMed Monnier L, Mas E, Ginet C, Michel F, Villo LN, Cristol JP, Colette C: Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006, 295: 1681-1687. 10.1001/jama.295.14.1681.CrossRefPubMed
20.
go back to reference Kubiak T, Hermanns N, Schreckling HJ, Kulzer B, Haak T: Assessment of hypoglycaemia awareness using continuous glucose monitoring. Diabet Med. 2004, 21: 487-490. 10.1111/j.1464-5491.2004.1136.x.CrossRefPubMed Kubiak T, Hermanns N, Schreckling HJ, Kulzer B, Haak T: Assessment of hypoglycaemia awareness using continuous glucose monitoring. Diabet Med. 2004, 21: 487-490. 10.1111/j.1464-5491.2004.1136.x.CrossRefPubMed
21.
go back to reference Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999, 22: 1462-1470. 10.2337/diacare.22.9.1462.CrossRefPubMed Matsuda M, DeFronzo RA: Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999, 22: 1462-1470. 10.2337/diacare.22.9.1462.CrossRefPubMed
22.
go back to reference Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006, 145: 247-254. 10.7326/0003-4819-145-4-200608150-00004.CrossRefPubMed Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F, Chronic Kidney Disease Epidemiology Collaboration: Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006, 145: 247-254. 10.7326/0003-4819-145-4-200608150-00004.CrossRefPubMed
23.
go back to reference Kohnert KD, Augstein P, Heinke P, Zander E, Peterson K, Freyse EJ, Salzsieder E: Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. Diabetes Res Clin Pract. 2007, 77: 420-426. 10.1016/j.diabres.2007.01.021.CrossRefPubMed Kohnert KD, Augstein P, Heinke P, Zander E, Peterson K, Freyse EJ, Salzsieder E: Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. Diabetes Res Clin Pract. 2007, 77: 420-426. 10.1016/j.diabres.2007.01.021.CrossRefPubMed
24.
go back to reference Hay LC, Wilmshurst EG, Fulcher G: Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technol Ther. 2003, 5: 19-26. 10.1089/152091503763816427.CrossRefPubMed Hay LC, Wilmshurst EG, Fulcher G: Unrecognized hypo- and hyperglycemia in well-controlled patients with type 2 diabetes mellitus: the results of continuous glucose monitoring. Diabetes Technol Ther. 2003, 5: 19-26. 10.1089/152091503763816427.CrossRefPubMed
25.
go back to reference Su JB, Wang XQ, Chen JF, Wu G, Jin Y: Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose. Chin Med J (Engl). 2011, 124: 144-147. Su JB, Wang XQ, Chen JF, Wu G, Jin Y: Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose. Chin Med J (Engl). 2011, 124: 144-147.
26.
go back to reference Takao T, Ide T, Yanagisawa H, Kikuchi M, Kawazu S, Matsuyama Y: The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: retrospective long-term follow-up. Diabetes Res Clin Pract. 2010, 89: 296-302. 10.1016/j.diabres.2010.03.027.CrossRefPubMed Takao T, Ide T, Yanagisawa H, Kikuchi M, Kawazu S, Matsuyama Y: The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: retrospective long-term follow-up. Diabetes Res Clin Pract. 2010, 89: 296-302. 10.1016/j.diabres.2010.03.027.CrossRefPubMed
27.
go back to reference Takao T, Ide T, Yanagisawa H, Kikuchi M, Kawazu S, Matsuyama Y: The effects of fasting plasma glucose variability and time-dependent glycemic control on the long-term risk of retinopathy in type 2 diabetic patients. Diabetes Res Clin Pract. 2011, 91: e40-e42. 10.1016/j.diabres.2010.10.009.CrossRefPubMed Takao T, Ide T, Yanagisawa H, Kikuchi M, Kawazu S, Matsuyama Y: The effects of fasting plasma glucose variability and time-dependent glycemic control on the long-term risk of retinopathy in type 2 diabetic patients. Diabetes Res Clin Pract. 2011, 91: e40-e42. 10.1016/j.diabres.2010.10.009.CrossRefPubMed
28.
go back to reference Kilpatrick ES, Rigby AS, Atkin SL: A1C variability and the risk of microvascular complications in type 1 diabetes: data from the diabetes control and complications trial. Diabetes Care. 2008, 31: 2198-2202. 10.2337/dc08-0864.PubMedCentralCrossRefPubMed Kilpatrick ES, Rigby AS, Atkin SL: A1C variability and the risk of microvascular complications in type 1 diabetes: data from the diabetes control and complications trial. Diabetes Care. 2008, 31: 2198-2202. 10.2337/dc08-0864.PubMedCentralCrossRefPubMed
29.
go back to reference Lin CC, Chen CC, Chen FN, Li CI, Liu CS, Lin WY, Yang SY, Lee CC, Li TC: Risks of diabetic nephropathy with variation in hemoglobin A1c and fasting plasma glucose. Am J Med. 2013, 126: 1017e1-1017e10.CrossRef Lin CC, Chen CC, Chen FN, Li CI, Liu CS, Lin WY, Yang SY, Lee CC, Li TC: Risks of diabetic nephropathy with variation in hemoglobin A1c and fasting plasma glucose. Am J Med. 2013, 126: 1017e1-1017e10.CrossRef
30.
go back to reference Sartore G, Chilelli NC, Burlina S, Lapolla A: Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol. 2013, 50: 437-442. 10.1007/s00592-013-0459-9.CrossRefPubMed Sartore G, Chilelli NC, Burlina S, Lapolla A: Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol. 2013, 50: 437-442. 10.1007/s00592-013-0459-9.CrossRefPubMed
31.
go back to reference Oyibo SO, Prasad YD, Jackson NJ, Jude EB, Boulton AJ: The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med. 2002, 19: 870-873. 10.1046/j.1464-5491.2002.00801.x.CrossRefPubMed Oyibo SO, Prasad YD, Jackson NJ, Jude EB, Boulton AJ: The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med. 2002, 19: 870-873. 10.1046/j.1464-5491.2002.00801.x.CrossRefPubMed
32.
go back to reference Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature. 2001, 414: 813-820. 10.1038/414813a.CrossRefPubMed Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature. 2001, 414: 813-820. 10.1038/414813a.CrossRefPubMed
33.
go back to reference Brownlee M: The pathophysiology of diabetic complications: a unifying mechanism. Diabetes. 2005, 54: 1615-1625. 10.2337/diabetes.54.6.1615.CrossRefPubMed Brownlee M: The pathophysiology of diabetic complications: a unifying mechanism. Diabetes. 2005, 54: 1615-1625. 10.2337/diabetes.54.6.1615.CrossRefPubMed
34.
go back to reference Torimoto K, Okada Y, Mori H, Tanaka Y: Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol. 2013, 12: 1-10.1186/1475-2840-12-1.PubMedCentralCrossRefPubMed Torimoto K, Okada Y, Mori H, Tanaka Y: Relationship between fluctuations in glucose levels measured by continuous glucose monitoring and vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol. 2013, 12: 1-10.1186/1475-2840-12-1.PubMedCentralCrossRefPubMed
35.
go back to reference Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, Zhou Y, Ma C: Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011, 10: 19-10.1186/1475-2840-10-19.PubMedCentralCrossRefPubMed Su G, Mi S, Tao H, Li Z, Yang H, Zheng H, Zhou Y, Ma C: Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol. 2011, 10: 19-10.1186/1475-2840-10-19.PubMedCentralCrossRefPubMed
36.
go back to reference Su G, Mi SH, Li Z, Tao H, Yang HX, Zheng H: Prognostic value of early in-hospital glycemic excursion in elderly patients with acute myocardial infarction. Cardiovasc Diabetol. 2013, 12: 33-10.1186/1475-2840-12-33.PubMedCentralCrossRefPubMed Su G, Mi SH, Li Z, Tao H, Yang HX, Zheng H: Prognostic value of early in-hospital glycemic excursion in elderly patients with acute myocardial infarction. Cardiovasc Diabetol. 2013, 12: 33-10.1186/1475-2840-12-33.PubMedCentralCrossRefPubMed
37.
go back to reference Su G, Mi SH, Tao H, Li Z, Yang HX, Zheng H, Zhou Y, Tian L: Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction. Diabetes Care. 2013, 36: 1026-1032. 10.2337/dc12-0925.PubMedCentralCrossRefPubMed Su G, Mi SH, Tao H, Li Z, Yang HX, Zheng H, Zhou Y, Tian L: Impact of admission glycemic variability, glucose, and glycosylated hemoglobin on major adverse cardiac events after acute myocardial infarction. Diabetes Care. 2013, 36: 1026-1032. 10.2337/dc12-0925.PubMedCentralCrossRefPubMed
38.
go back to reference Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MH, Matthews DR: The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetol Metab Syndr. 2012, 4: 21-10.1186/1758-5996-4-21.PubMedCentralCrossRefPubMed Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MH, Matthews DR: The prevalence, patterns and predictors of diabetic peripheral neuropathy in a developing country. Diabetol Metab Syndr. 2012, 4: 21-10.1186/1758-5996-4-21.PubMedCentralCrossRefPubMed
39.
go back to reference Pop-Busui R, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, Green J, Palumbo P, Perkins BA, Whitehouse F, Jones TL, BARI 2D Study Group: Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) cohort. Diabetes Care. 2013, 36: 3208-3215. 10.2337/dc13-0012.PubMedCentralCrossRefPubMed Pop-Busui R, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, Green J, Palumbo P, Perkins BA, Whitehouse F, Jones TL, BARI 2D Study Group: Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the bypass angioplasty revascularization investigation 2 diabetes (BARI 2D) cohort. Diabetes Care. 2013, 36: 3208-3215. 10.2337/dc13-0012.PubMedCentralCrossRefPubMed
Metadata
Title
The relationship between glycemic variability and diabetic peripheral neuropathy in type 2 diabetes with well-controlled HbA1c
Authors
Feng Xu
Li-hua Zhao
Jian-bin Su
Tong Chen
Xue-qin Wang
Jin-feng Chen
Gang Wu
Yan Jin
Xiao-hua Wang
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diabetology & Metabolic Syndrome / Issue 1/2014
Electronic ISSN: 1758-5996
DOI
https://doi.org/10.1186/1758-5996-6-139

Other articles of this Issue 1/2014

Diabetology & Metabolic Syndrome 1/2014 Go to the issue